For anyone who has experienced the misfortune
of receiving a cancer diagnosis, they will have likely
had occasion to review a formal Histopathology Report,
describing the nature and character of a tissue sample
obtained from their body, which contains
information like this:

This report is produced by a Pathologist who
carefully examines the tissue extracted from a
patient’s body under a microscope,
observing the following:

Hence, one is formally diagnosed with disease.
While valuable, it may be difficult to re-perform
this type of analysis, and therefore PET/CT
(Positron Emission Tomography/Computerized
Tomograpy) imaging is normally used to
assess cancers, throughout the course of
treatment, producing images such as this:

Again, while valuable, PET/CT imaging is
expensive and cumbersome to perform.
Therefore, Liquid Biopsy, which can be
utilized to count the number of
Circulating Tumor Cells derived from
a volume of blood, can offer a simple and
expeditious means of gaining insight
into disease, and most importantly,
if in fact interventions deployed to
combat disease, are actually working.

Notably, a convenient blood draw can
be performed at any frequency desired
offering insight into how many CTCs
are present in one’s body:

Liquid Biopsy tests can detect CTCs
for any type of cancer with the
exception of Brain Cancers or
Encapsulated Tumors.

To learn more about what the
RGCC Liquid Biopsy test can
offer, click here to download a sample
report:

Onconomics Plus Test
Oncotrace Test